logo

Myriad Genetics Inc. (MYGN)



Trade MYGN now with
  Date
  Headline
5/8/2018 6:43:47 AM Myriad Genetics Inc. (MYGN) Has Raised Its 2018 EPS Estimate To 1.19 - 1.21 From 1.11 - 1.16
5/8/2018 6:43:15 AM Myriad Genetics Inc. (MYGN) Has Raised Its 2018 Revenue Estimate To $771 - $773 Mln From $760 - $770 Mln
5/8/2018 6:31:10 AM Myriad Genetics Q3 Adjusted EPS $0.31 Vs $0.27 Last Year
4/2/2018 7:13:16 AM Myriad Gets Pre-Market Approval For BRACAnalysis Diagnostic System In Japan
3/6/2018 7:06:32 AM Myriad Genetics Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer
3/1/2018 7:09:42 AM Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer
2/7/2018 7:06:36 AM Myriad: MyRisk Hereditary Cancer Test Finds Over 12% Of Men With Prostate Cancer Carry An Inherited Genetic Mutation
2/6/2018 4:19:05 PM Myriad Genetics Inc. (MYGN) Has Raised Its FY18 EPS Estimate To 1.11 - 1.16 From 1.00 - 1.05
2/6/2018 4:18:26 PM Myriad Genetics Inc. (MYGN) Has Raised Its FY18 Revenue Estimate To $760 Mln - $770 Mln From $750 Mln - $770 Mln
2/6/2018 4:08:19 PM Myriad Genetics Q2 GAAP EPS Of $0.45 And Adjusted EPS $0.31
1/22/2018 7:08:34 AM Myriad Applauds Consensus Statement From Intl. Expert Panel On Screening Recommendations For Hereditary Prostate Cancer
1/3/2018 7:06:32 AM Myriad Genetics Reports Expanded Research Collaboration With AstraZeneca